Haleon PLC — Major Shareholding Notification 2025

Feb 26, 2025

6-K 1 a6037y.htm HOLDING(S) IN COMPANY Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com Copyright 2025 Issuer Direct Corporation a6037y

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	26
February 2025 - “Holding(s) in Company”

99.1

26 February 2025

HALEON PLC

("Haleon" or "the Company")

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BMX86B70

Issuer Name

HALEON PLC

UK or Non-UK Issuer

UK

1. Reason for Notification

Other

Comments

Conversion of American depositary shares into ordinary shares

1. Details of person subject to the notification obligation

Name

Pfizer Inc.

City of registered office (if applicable)

New York

Country of registered office (if applicable)

United States of America

1. Details of the shareholder

| Name | City
of registered office | Country
of registered office |
| --- | --- | --- |
| State
Street Nominees Limited | London | United
Kingdom |

1. Date on which the threshold was crossed or reached

24-Feb-2025

1. Date on which Issuer notified

26-Feb-2025

1. Total positions of person(s) subject to the notification obligation

| | %
of voting rights attached to shares (total of 8.A) | %
of voting rights through financial instruments (total of 8.B 1 +
8.B 2) | Total
of both in % (8.A + 8.B) | Total
number of voting rights held in issuer |
| --- | --- | --- | --- | --- |
| Resulting situation
on the date on which threshold was crossed or reached | 7.310000 | 0.000000 | 7.310000 | 661709764 |
| Position of
previous notification (if applicable) | 7.310000 | 0.000000 | 7.310000 | |

1. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	% of direct voting rights (DTR5.1)
Ordinary Shares
GB00BMX86B70	661709764	7.310000
Sub
Total 8.A	661709764	7.310000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument
Sub
Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument
Sub
Total 8.B2

1. Information in relation to the person subject to the notification obligation

2. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person Name of controlled undertaking % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold

1. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

1. Additional Information

This notification relates to the conversion by Pfizer Inc. ("Pfizer") of its holding of American depositary shares representing ordinary shares of Haleon plc ("Haleon") into Haleon ordinary shares. These calculations are based on Haleon's issued voting share capital of 9,054,145,714 ordinary shares with voting rights, as communicated by Haleon in its announcement on total voting rights and capital dated 3 February 2025. Pfizer holds its Haleon ordinary shares through State Street Nominees Limited, which holds the legal title to those shares on Pfizer's behalf.

1. Date of Completion

26-Feb-2025

1. Place Of Completion

New York, USA

Amanda Mellor, Company Secretary

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| HALEON PLC (Registrant) — /s/
Amanda Mellor | |
| --- | --- |
| Name: | Amanda
Mellor |
| Title: | Company
Secretary |